Uppsala University Hospital, in collaboration with Viedoc, is launching Grand SLAM, an interventional study focused on reducing the length of adjuvant immunotherapy for malignant melanoma patients while maintaining efficacy. Viedoc's electronic Case Report Form (eCRF) will facilitate efficient data management for the study.
According to Professor Gustav Ullenhag, a leading expert in cancer immunotherapy and senior oncologist at Uppsala University Hospital, Grand SLAM (Short, Long, Adjuvant, malignant Melanoma) is the largest drug study in malignant melanoma patients ever launched by a Swedish initiative.
Uppsala University Hospital, one of Sweden's leading academic medical centers, located in Uppsala and known for its advanced cancer care, is leading this effort, with the aim of including 1,880 patients. The European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group is in favor of the study.
“Melanoma is the form of skin cancer responsible for the highest number of deaths, with 535 lives claimed in Sweden in 2022,” explains Ullenhag. “This study aims to shorten treatment duration from 12 to 6 months, thereby reducing side effects and healthcare resources, including drug costs. Billions of SEK are spent worldwide each year on adjuvant immunotherapy for cancer patients.”
Viedoc’s electronic Case Report Form (eCRF) will be the primary tool for data collection during the study. Over time, Viedoc's platform may also be used for data compilation and reporting, offering a comprehensive solution for streamlining clinical research.
“Grand SLAM is not only a pan-Nordic initiative, and involves, in addition to several Swedish county hospitals, all university medical centers in Sweden, Norway and except one in Finland; several other countries will hopefully join, and so far, Italy, France and the Netherlands have expressed an interest in participating,” says Ullenhag. He adds, “These collaborations underscore the study's broader European impact and could pave the way for similar studies in other cancer types, influencing broader oncology practices.”
